Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Epidermal Growth Factor (EGF) has some scientific validation for its use in supporting or treating dermatitis, particularly in the context of atopic dermatitis and wound healing. EGF is a polypeptide that stimulates cell growth, proliferation, and differentiation by binding to its receptor, EGFR, on the cell surface. Several studies and clinical trials have investigated topical application of EGF in patients with various skin conditions, including dermatitis. For example, randomized controlled trials have demonstrated that topical EGF can accelerate healing of skin lesions, improve barrier function, and reduce inflammation in models of atopic dermatitis and other skin injuries. A 2018 study published in the "Annals of Dermatology" found that EGF ointment aided the repair of skin barrier function and reduced symptoms in patients with atopic dermatitis. Another 2015 study reported improved wound healing and reduced inflammatory markers in animal models treated with EGF.

However, while these results are promising, the body of evidence is not yet extensive or universally conclusive, and EGF is not a standard first-line therapy for dermatitis. Most studies have small sample sizes or are preclinical, and long-term safety data are limited. Nevertheless, the mechanism of action and available research provide a scientific rationale for its use as an adjunctive therapy in certain cases of dermatitis, especially where wound healing is impaired. More large-scale, high-quality clinical trials are needed to fully establish EGF’s efficacy and safety profile for routine treatment of dermatitis.

More about Epidermal Growth Factor
More about Dermatitis

Other ingredients used for Dermatitis

Other health conditions supported by Epidermal Growth Factor

Products containing Epidermal Growth Factor